Friday, November 13, 2026 · Five AI analysts screened this index for stocks with the best shot at gaining +5% within 30 days
Neutral Normal choppiness · VIX 19.2
The market shows a sharp rotation away from high-growth tech and semiconductors (NVDA, INTC, DELL, GOOGL, CSCO all down double digits over 30 days) into defensive, healthcare, and industrial/business-services names that are hugging their 52-week highs with steady 5-day and 30-day gains. Breadth is highly bifurcated rather than broadly bullish or bearish, so near-term 5%+ setups are concentrated in names showing genuine sustained strength rather than single-day pops.
Which of today's picks to actually take, and at what size, given what you are already holding. Each pick's own Suggested Allocation sizes it in isolation; this table applies the portfolio limits — at most 20 open positions and 60% of the portfolio committed in total. Run with --capital 25000 to see these sizes as order amounts rather than percentages.
| Rank | Stock | Action | Size | Entry → Target | Notes |
|---|---|---|---|---|---|
| #1 | KO | SKIP | — | $99.16 → $104.12 stop $91.23 |
Half-Kelly sizes this at 0% — the odds carry no edge worth capital. |
| #2 | FTV | SKIP | — | $67.79 → $71.18 stop $62.03 |
Half-Kelly sizes this at 0% — the odds carry no edge worth capital. |
| #3 | JNJ | SKIP | — | $286.33 → $300.65 stop $266.86 |
Position cap reached — 98 of 20 slots in use. |
| #4 | COR | SKIP | — | $358.43 → $376.35 stop $333.34 |
Position cap reached — 98 of 20 slots in use. |
Already open: UNH (to Nov 14), ULVR.L (to Nov 18), PFE (to Nov 19), ROST (to Nov 19), CSX (to Nov 21), TRV (to Nov 22), SGE.L (to Nov 25), SVT.L (to Nov 25), NSC (to Nov 26), RTX (to Nov 27), SO (to Nov 27), CNA.L (to Nov 27) … and 86 more. Symbols you already hold were excluded from this run's candidates rather than re-picked.
Position-sizing guidance only — half-Kelly per pick, bounded by the limits above. Not personal investment advice.
Coca-Cola makes soft drinks and other beverages sold almost everywhere in the world. The company beat earnings expectations and raised its full-year guidance with confident language from management, and the stock is sitting right at its 52-week high. The main risk is that the stock looks quite overbought after its run, and insiders have been selling rather than buying.
Why the AI likes it
What could go wrong
Calibrated probability: 59% (raw model estimate: 66%) — adjusted using the accuracy of past resolved picks.
Trade math
Suggested allocation is half-Kelly sizing guidance capped at 10% — not personal investment advice. Allocations are scaled to 85% of half-Kelly for the current market regime.
What each AI analyst estimated
Fortive makes industrial and workplace-safety technology products. The company beat earnings expectations and raised its full-year profit guidance with confident language from management, continuing a streak of double-digit profit growth. The main risks are that company insiders have been selling stock and shares already look somewhat overbought after a 17% rally in the past month.
Why the AI likes it
What could go wrong
Calibrated probability: 59% (raw model estimate: 63%) — adjusted using the accuracy of past resolved picks.
Trade math
Suggested allocation is half-Kelly sizing guidance capped at 10% — not personal investment advice. Allocations are scaled to 85% of half-Kelly for the current market regime.
What each AI analyst estimated
Johnson & Johnson makes medicines, medical devices, and consumer health products. Its stock has climbed steadily this month, outpacing the broader market by a wide margin, and the trend looks technically healthy rather than overheated. The main risk is that after such a strong run, some profit-taking could cool the rally.
Why the AI likes it
What could go wrong
Calibrated probability: 59% (raw model estimate: 67%) — adjusted using the accuracy of past resolved picks.
Trade math
Suggested allocation is half-Kelly sizing guidance capped at 10% — not personal investment advice. Allocations are scaled to 85% of half-Kelly for the current market regime.
What each AI analyst estimated
Cencora distributes pharmaceuticals and health products to pharmacies and hospitals. Its shares have been accelerating recently, gaining over 7% in just the last five days, and are clearly outperforming the broader market with no signs of being overbought. The main risk is that it trades fewer shares daily than mega-cap names, which can mean sharper price swings.
Why the AI likes it
What could go wrong
Calibrated probability: 59% (raw model estimate: 66%) — adjusted using the accuracy of past resolved picks.
Trade math
Suggested allocation is half-Kelly sizing guidance capped at 10% — not personal investment advice. Allocations are scaled to 85% of half-Kelly for the current market regime.
What each AI analyst estimated
This report identifies stocks with an AI-assessed probability of gaining +5% within 30 calendar days (target exit by December 13, 2026). Picks are ranked by how many independent AI agents agreed — more agreement means higher conviction. The guide below tells you exactly how to act on them.
Step-by-Step Action Plan
Position Sizing by Conviction Tier
Size each position according to the coloured border on its pick card. Cap your total exposure across all picks from this report at 25% of your overall trading budget.
| Agents Agreeing | What It Means | Max Allocation Per Pick |
|---|---|---|
| 5/5 | Highest conviction — all five independent analytical checks passed | Up to 10% |
| 4/5 | Very high conviction — four of five independent checks aligned | Up to 8% |
| 3/5 | High conviction — three agents independently agreed | Up to 6% |
| 2/5 | Moderate conviction — two agents independently agreed | Up to 4% |
| 1 Agent | Speculative — solo pick, admitted only at Very High confidence | Up to 2% |
The Three Exit Rules
A plain-English guide to every figure shown on each pick card — what it means, how it is calculated, and what a good or bad value looks like.
Scout scanned 503 S&P 500 constituents and short-listed 27 candidates for deep analysis by the five analysts. Here is what happened to each one.
Checks 30-day price history for every candidate before making any selection. Requires positive period return and positive 5-day momentum as mandatory gates. Ranks picks by proximity to their period high and adjusts probability based on volume. Uses news only to rule out major negative catalysts.
Searches earnings results, analyst upgrades, and revenue trends before checking price data. Requires at least one verifiable fundamental catalyst — earnings beat, analyst upgrade, or revenue acceleration — within the last 60 days. Favours stocks with strong fundamentals trading below recent highs (value entry).
Hunts for specific events within the last 21 days: FDA approvals, major contract wins, product launches, earnings surprises, or significant analyst upgrades. Requires a positive price reaction confirming the market is recognising the catalyst. Also scans for upcoming events that could drive further gains.
Maps the macroeconomic regime (risk-on / risk-off / neutral) and identifies sectors benefiting from current conditions before looking at individual stocks. Only selects stocks from macro-aligned sectors with confirmed sector tailwinds. Adjusts for interest rate sensitivity and geopolitical factors.
Reviews the final picks after all four analysts agree and actively challenges each bull thesis. Searches for bearish technical signals, negative news, insider selling, and elevated short interest that the agreeing agents may have underweighted. Produces evidence-based counter-arguments shown on each pick card.
Pure-quant analyst: no news, no narrative, only numbers. Identifies mean-reversion setups from RSI extremes (<35) with momentum turning, Bollinger squeeze breakouts, and multi-factor quant scores using RSI, MACD, OBV, short interest, and insider transaction data. Counterbalances narrative bias across the four analyst agents.